Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well
it works in treating young patients with solid tumors or anaplastic large cell lymphoma that
has returned after a period of improvement or does not respond to treatment. Crizotinib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
(Phase 1 completed 2/15/13)